Bright Minds Biosciences Inc Overview
Industry: Biotechnology
Sector: Healthcare
Bright Minds Biosciences Inc., a biotechnology company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York. Bright Minds Biosciences Inc., a biotechnology company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neurop Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Bright Minds Biosciences Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Net loss was -$18M (from $2.9M).
Net loss
-$18M
from $2.9M
What changed
- Net loss was -$18M (from $2.9M).
Guidance / outlook
The Company expects to continue to raise additional capital through dilutive equity financings and seek additional investment opportunities to further the development of therapeutics to improve the lives of patients with certain severe and life-altering diseases.
Earnings material
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
US FDA approves Outlook Therapeutics' eye disease drug
Headline from Reuters: US FDA approves Outlook Therapeutics' eye disease drug.
US FDA approves Celcuity's breast cancer drug
Headline from Reuters: US FDA approves Celcuity's breast cancer drug.
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
Headline from Reuters: FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug.
AI shortens drug discovery to around 1 year in China, Insilico CEO says
Headline from Reuters: AI shortens drug discovery to around 1 year in China, Insilico CEO says.
U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns
Headline from CNBC: U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns.
Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application
Headline from Reuters: Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application.
Earnings Per Share
Score 0.00/5
Bright Minds Biosciences Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
Return on Equity
Score 3.37/5
Bright Minds Biosciences Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 3.69/5
Bright Minds Biosciences Inc
commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 4.31/5
Bright Minds Biosciences Inc
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios